Obesity drug access in the UK now runs along two tracks that rarely meet. One is a publicly funded NHS rollout of tirzepatide (Mounjaro), phased over as long as 12 years. The other is a private market that has grown far faster. A UCL survey estimates that about 1.6 million British adults used these medicines for weight loss in one year. Two oral GLP-1 tablets have since arrived, both on private prescription only.
This article sets out where obesity drug access stands in September 2026. It covers who qualifies on the NHS and what private patients pay. It also covers regulatory oversight and the decisions ahead.
How the NHS funds obesity drug access in England
The National Institute for Health and Care Excellence (NICE) recommended tirzepatide in technology appraisal TA1026, published on 23 December 2024. It covers adults with an initial body mass index (BMI) of at least 35 kg/m². They must also have at least one weight-related comorbidity. NHS England estimates that this population numbers 3.4 million people.
NICE accepted a funding variation requested by NHS England. As a result, the full eligible population should gain access within a maximum of 12 years. The first three years target around 220,000 patients. LSDN has examined what that 12-year queue means for newer agents in its retatrutide Phase 3 analysis.
From 24 March 2025, integrated care boards (ICBs) had to fund treatment in specialist weight management services. That duty covers anyone meeting the NICE criteria. Primary care followed from 23 June 2025, but only for prioritised cohorts set by NHS England.
Cohort I requires a BMI of 40 or more plus at least four of five qualifying conditions. These are hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes. Cohort II lowers the BMI band to 35 to 39.9, with the same four-condition test. NHS England schedules it for 2026/27, over an estimated nine months. Cohort III then admits people with a BMI of 40 or more and three qualifying conditions. Thresholds fall by 2.5 kg/m² for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds.
Wraparound support covering diet and behaviour change is mandatory. Where ICBs provide it themselves in primary care, it must run for at least nine months. Clinicians should reassess treatment if a patient has not lost 5 per cent of initial weight after six months. That test applies at the highest tolerated dose. Other NICE-recommended weight management medicines currently carry a two-year maximum. Tirzepatide has no set stopping rule.
The April 2026 funding switch
NHS England reviewed its interim commissioning guidance in April 2026. Primary care management costs now sit within the Quality and Outcomes Framework (QOF) for 2026/27. Two new indicators, OB004 and OB005, cover identifying adults living with obesity and considering medicines where appropriate. The switch changes how obesity drug access is paid for in general practice. GP participation is optional, however. NHS Cheshire and Merseyside tells patients that meeting the criteria does not guarantee access to treatment.
Why NHS obesity drug access has lagged
Early delivery fell short of the national plan. An investigation by The BMJ was published in September 2025. It found that only 18 of 42 ICBs had started prescribing in line with the rollout. Just nine confirmed funding for at least 70 per cent of their eligible patients.
Jonathan Hazlehurst of the University of Birmingham said year-one funding “clearly only covers approximately 10%” of the three-year target. Ellen Welch, co-chair of Doctors’ Association UK, was blunter. She said: “These figures confirm the fear that the roll out is not fit for purpose.” A follow-up BMJ report in January 2026 found that a fifth of areas still lacked NHS access.
The most detailed evidence on NHS obesity drug access comes from a national evaluation known as NEWA. The study, the National Evaluation of Weight Medication Access, is funded by the National Institute for Health and Care Research. Its first paper, posted to medRxiv on 27 July 2026, has not yet been peer reviewed. Of 39 ICBs with information on access criteria, eight applied extra local prioritisation because of funding constraints. The team found no detectable rise in obesity-related tirzepatide prescribing between June 2025 and January 2026, beyond background diabetes trends.
Measurement is part of the problem. NHS England Digital notes that tirzepatide carries one brand name for both diabetes and obesity. That makes the two uses hard to separate in prescribing data. NEWA stakeholders also held mixed views on the QOF switch. Some feared that uneven GP participation could widen health inequalities.
Private obesity drug access has outgrown the NHS
The clearest measure of demand comes from a UCL study published in BMC Medicine in January 2026. Its lead author is Professor Sarah Jackson. It drew on a nationally representative survey carried out between January and March 2025. An estimated 2.9 per cent of adults, about 1.6 million people, had used a GLP-1 medicine for weight loss. That use fell within the previous year. Around 910,000 used one exclusively for that purpose. Of that group, 80.2 per cent reported using Mounjaro. The survey did not ask where medicines came from, and it predates the June 2025 primary care rollout.
A further 3.3 million adults said they were interested in starting. Interest was higher among people facing greater socioeconomic disadvantage. Jackson said: “This usage far exceeds NHS England’s initial goal of prescribing these drugs to 220,000 people over three years.”
Price is the main barrier to private obesity drug access. Eli Lilly raised the UK list price of Mounjaro from 1 September 2025. Monthly list prices moved from between £92 and £122 to between £133 and £330, depending on dose. Lilly said there would be no increase to the price paid by the NHS at present. Lilly called the change “aligning the list price more consistently to ensure fair global contributions to the cost of innovation.”
Oral options are now reshaping that market. Novo Nordisk announced UK approval of the Wegovy pill (semaglutide tablets) on 11 June 2026. On 10 August 2026, the MHRA authorised orforglipron (Foundayo), the first approval of the tablet in Europe. Julian Beach, MHRA Executive Director of Healthcare Quality and Access, said “this is a prescription-only medication”.
Lilly launched Foundayo privately on 24 August. The company said it would likely be priced between £100 and £120 a month, Reuters reported. Private providers were pricing starter doses of the Wegovy pill at £74 to £129 a month. At those quoted prices, both tablets sit below the lowest Mounjaro list price of £133. Provider prices and list prices are not directly comparable, however. Earlier coverage of the Foundayo approval sits in LSDN’s obesity drug news and approval watch.
Regulators tighten the private route
Growth in private obesity drug access has brought closer scrutiny of online supply. In April 2026, the General Pharmaceutical Council (GPhC) published a themed review of inspection reports and concerns. It covered January 2024 to December 2025. Many pharmacies were delivering these services appropriately, the regulator said, but standards were not always met.
Reviewers found weaknesses in risk assessment, clinical governance and consultation records. Processes for independently verifying weight and BMI were inconsistent. Arrangements for ongoing clinical follow-up were often limited. Roz Gittins, the GPhC’s Chief Pharmacy Officer, said: “This is about more than compliance.”
The same standards reach into the NHS. NHS England requires commissioned online pathways to comply with GPhC guidance. For high-risk medicines such as tirzepatide, prescribing decisions cannot rest solely on an online questionnaire.
The next decisions on obesity drug access
Three processes will shape the coming year. The first is the NICE appraisal of orforglipron, reference ID6516. Its project page lists a committee meeting on 14 July 2026 and expected publication on 18 November 2026. However, a NICE spokesperson told Reuters in August that it had requested further information, with no second committee date set. LSDN found no draft guidance on the project page as at 19 September 2026 and draws no conclusion about timing.
The second is the Obesity Pathway Innovation Programme. Twelve projects were named on 27 June 2026 and will run until March 2029. They share grant funding of up to £50 million from government and up to £35 million from Lilly. Lilly worked with the Department for Science, Innovation and Technology and Innovate UK on the competition design. The government states that Lilly screened applications for eligibility but was not involved in selecting them. James Murray, then Health Secretary, said: “Obesity is an epidemic and we need bold action to end it now.”
The third is NICE’s formal review of the funding variation. It is due no later than three years after the December 2024 guidance.
Obesity drug access also differs across the UK. The Scottish Medicines Consortium accepted tirzepatide for restricted use in June 2024. Its threshold is a BMI of 30 or more with at least one weight-related comorbidity. In September 2024, an NHS Scotland consensus statement prioritised a BMI of 38 or more for the first phase. Even so, NHS Lanarkshire says it can prescribe only on a very limited basis, in exceptional circumstances.
LSDN reads the pattern as four separate gates: licensing, recommendation, funding and delivery. Regulators have cleared new products quickly, while NHS funding and delivery follow a 12-year timetable. Until those gates align, obesity drug access in the UK will depend on where people live and what they pay.
